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CORRESPONDENCE
international rates of hip fractures are
higher in countries where calcium
consumption is high. 5
Prevention of osteoporosis does not
depend on calcium, but rather in
preserving the bone matrix, which
depends on the fine control of osteoblast
and octeoclast activity.
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Sir—As South Africa is in the dock for
trying to produce affordable drugs for its
HIV positive population, it would be
more appropriate to deliver a guilty
verdict on the multinational pharma-
ceutical companies using the WTO
regulations to prosecute this case.
But while the latter try to prevent
less-developed countries such as South
Africa, Brazil, and India from producing
their own cheaper HIV drugs, govern-
ments in more-developed countries
seem reluctant to challenge this. They
seem to expect higher ethical self-
regulation from drug companies, wish-
fully thinking that consideration for the
well-being of all human beings will tem-
per those companies’ drive for profit.
The tackling of HIV takes more than
drugs, cheap or not. People with HIV
infection need clean water, good
housing, employment, freedom from
war, and starvation if the drugs are to
work for them. However, to ensure that
we are all healthy is not amenable to the
profit motive of the pharmaceuticals,
who exist to make money for the few.
Public health cannot be left to private
hands.
And, after 4 years of promising, our
own government should finally produce
its HIV strategy and make clear its
contribution to tackling HIV, here and
worldwide, including calling for the
companies to drop their lawsuits against
less-developed countries such as South
Africa, and calling for all other
governmental and non-governmental
organisations to join in this demand.
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Trade systems in less-
developed countries
Sir—In your Jan 27 editorial1 you note
the limitations of the multilateral trade
system in meeting the needs of 
poor countries. The World Trade,
Organisation (WTO) agreement on
trade-related features of intellectual
property rights (TRIPS) obliges all
member states to provide a minimum of
20-year patent protection for medicines.
This system will affect access to
medicines because prices, especially 
for new drugs, will increase and the
extended global protection of pharma-
ceutical patents will stifle generic
competition.
In the TRIPS agreement, potentially
negative effects of patent protection are
recognised by allowing for compulsory
licences and parallel imports. But
whether less-developed countries will be
able to make use of such safeguards
remains to be seen. The omens are not
good. So far, where such countries have
tried to build them into national law,
more-developed countries have faced
legal action in the case of South Africa. 
South Africa is under fire for trying to
simplify procedure by giving the
Minister of Health the mandate to issue
a compulsory licence and parallel
imports. The US has now brought
Brazil before a WTO dispute settlement
body for its legislation on compulsory
licensing that requires a patent holder to
produce in Brazil. This move could over
time affect the country’s successful
AIDS programme that is heavily reliant
on the ability to locally produce cheap
medicines. By use of affordable generic
antiretrovirals the programme has
managed to cut mortality rates by
around 50%.
Pharmaceutical manufacturers
should withdraw from the case against
South Africa. Governments in more-
developed countries should support
governments trying to develop laws that
will enable them to increase access to
medicines that their populations
urgently need. Seemingly generous
offers of price discounts and donor
assistance will mean very little if
governments in poorer countries are not
allowed to let public-health interest
prevail over commercial interest. 
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Seizures after buproprion
overdose
Sir—A woman aged 19 years
presented with an altered mental
state, agitation, and auditory and
visual hallucinations. She had a
resting tachycardia and generally
increased tone and reflexes. She
denied taking recreational drugs. 
Shortly after admission she had 
two brief generalised seizures. A
standard toxicology screen show 
no cause of these. Because of 
clinical concern about the possible
contribution of 3,4-methylenedioxy-
methamphetamine (MDMA [Ecstasy]),
she was pressed on this issue. She
denied recreational drug use but
admitted to having taken 3·75 g of
bupropion (25 tablets) after a
domestic dispute. She had no 
further seizures and was discharged
the next day.
Bupropion is a novel monocyclic
antidepressant that was noted
incidentally to have a potent effect on
reducing nicotine dependence. The
drug substantially augments smoking
cessation rates and has been licensed
in the UK for this purpose.1,2
Bupropion and MDMA share
common structural similarities with
amphetamines and their similarities in
overdose are, therefore, unsurprising.
The symptoms are thought to be
related to dopamine re-uptake
inhibition and include hallucinations,
seizures, cardiotoxic effects, and
death.3-5
Smoking kills half of all regular
tobacco users and, therefore,
bupropion is an important new drug.
Clinicians in the UK should be aware
of its potential for toxic effects,
especially in overdose, since
widespread media publicity has
resulted in a substantial increase in its
use in the community.
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